Journal
CLINICAL INFECTIOUS DISEASES
Volume 74, Issue 2, Pages 288-293Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciab346
Keywords
SARS-CoV-2; Healthcare Workers; Antibodies; Seroprevalence
Categories
Funding
- Wellcome Trust [220991/Z/20/Z, 203077/Z/16/Z]
- Department for International Development (DFID)/Medical Research Council/National Institute for Health Research (NIHR)/Wellcome Trust [MR/R006083/1, 214320, 220985/Z/20/Z, 107568/Z/15/Z]
- Bill & Melinda Gates Foundation [INV-017547]
- Foreign Commonwealth and Development Office through the East Africa Research Fund [EARF/ITT/039]
- NIHR Health Protection Research Unit in Immunisation
- United Kingdom's Medical Research Council
- Department for International Development (African research leader fellowship) [MR/S005293/1]
- NIHR Mucosal Pathogens Research Unit at University College London (London School of Hygiene and Tropical Medicine) [2268427]
- Oak Foundation
- DELTAS Africa Initiative [DEL-15-003]
- Department for International Development
- National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance [HHSN272201400008C]
- Bill and Melinda Gates Foundation [INV-017547] Funding Source: Bill and Melinda Gates Foundation
- Wellcome Trust [220985/Z/20/Z, 220991/Z/20/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
The study reveals significant regional differences in seroprevalence of antibodies to SARS-CoV-2 among healthcare workers in Kenya, but no differences based on professional cadre.
In this study of antibodies to severe acute respiratory syndrome coronavirus 2 among healthcare workers in 3 counties in Kenya, we found significant regional differences in seroprevalence but no differences according to professional cadre. Background Few studies have assessed the seroprevalence of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among healthcare workers (HCWs) in Africa. We report findings from a survey among HCWs in 3 counties in Kenya. Methods We recruited 684 HCWs from Kilifi (rural), Busia (rural), and Nairobi (urban) counties. The serosurvey was conducted between 30 July and 4 December 2020. We tested for immunoglobulin G antibodies to SARS-CoV-2 spike protein, using enzyme-linked immunosorbent assay. Assay sensitivity and specificity were 92.7 (95% CI, 87.9-96.1) and 99.0% (95% CI, 98.1-99.5), respectively. We adjusted prevalence estimates, using bayesian modeling to account for assay performance. Results The crude overall seroprevalence was 19.7% (135 of 684). After adjustment for assay performance, seroprevalence was 20.8% (95% credible interval, 17.5%-24.4%). Seroprevalence varied significantly (P < .001) by site: 43.8% (95% credible interval, 35.8%-52.2%) in Nairobi, 12.6% (8.8%-17.1%) in Busia and 11.5% (7.2%-17.6%) in Kilifi. In a multivariable model controlling for age, sex, and site, professional cadre was not associated with differences in seroprevalence. Conclusion These initial data demonstrate a high seroprevalence of antibodies to SARS-CoV-2 among HCWs in Kenya. There was significant variation in seroprevalence by region, but not by cadre.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available